Milestone Scientific

MLSS

Market cap $27.4M

Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board Financing Strengthens Balance Sheet and Supports Commercial Growth Strategy; Backed by Long-Term Investors Including CEO and Chairman of the Board

Milestone Scientific Inc. (MLSS) Q4 2025 Earnings Call Transcript

Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025.

ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced that it will host a conference call at 8:30 AM Eastern Time on Wednesday, April 1, 2026, to discuss the company's financial results for the fourth quarter and full year ended December 31, 2025, as well as the company's corporate progress and other developments.

ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program.

Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months

Milestone Scientific Inc. ( MLSS ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Eric Hines - Chief Executive Officer, President & Director Keisha Harcum - Vice President of Finance Conference Call Participants David Waldman - Crescendo Communications, LLC Anthony Vendetti - Maxim Group LLC, Research Division Bruce Jackson - The Benchmark Company, LLC, Research Division Presentation Operator Greetings, and welcome to the Milestone Scientific Third Quarter 2025 Financial Results and Business Update Call. [Operator Instructions] And please note, this conference is being recorded.

ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives.

ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company's financial results for the third quarter ended September 30, 2025, as well as the company's corporate progress and other developments.

Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone Scientific for accelerated growth and improved financial performance Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone Scientific for accelerated growth and improved financial performance